Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Assets: 2020-2024

Historic Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $284.0 million.

  • Foghorn Therapeutics' Assets fell 33.53% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.0 million, marking a year-over-year decrease of 33.53%. This contributed to the annual value of $284.0 million for FY2024, which is 0.68% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Assets is $284.0 million, which was down 0.68% from $285.9 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Assets ranged from a high of $519.8 million in FY2021 and a low of $255.6 million during FY2020.
  • Over the past 3 years, Foghorn Therapeutics' median Assets value was $285.9 million (recorded in 2023), while the average stood at $324.9 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 103.36% in 2021, then fell by 29.38% in 2023.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Assets stood at $255.6 million in 2020, then skyrocketed by 103.36% to $519.8 million in 2021, then declined by 22.10% to $404.9 million in 2022, then dropped by 29.38% to $285.9 million in 2023, then dropped by 0.68% to $284.0 million in 2024.